The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children-Reference-Cited by-同舟云学术

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children

Published:2016-04-25 Issue:1 Volume:82 Page:185-198
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Bienczak Andrzej¹,Cook Adrian²,Wiesner Lubbe¹,Olagunju Adeniyi³,Mulenga Veronica⁴,Kityo Cissy⁵,Kekitiinwa Addy⁶,Owen Andrew³,Walker A. Sarah²,Gibb Diana M.²,McIlleron Helen¹,Burger David⁷,Denti Paolo¹

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine; University of Cape Town; Cape Town South Africa

2. MRC Clinical Trials Unit at University College London; London UK

3. Department of Molecular and Clinical Pharmacology; University of Liverpool; Liverpool UK

4. University Teaching Hospital, Department of Paediatrics and Child Health; Lusaka Zambia

5. Joint Clinical Research Centre; Kampala Uganda

6. Baylor College of Medicine Bristol Myers Squibb Children's Clinical Centre of Excellence, Kampala, Uganda / Gulu Regional Centre of Excellence; Gulu Uganda

7. Department of Pharmacy; Radboud University Nijmegen Medical Centre; Nijmegen the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12934/fullpdf

Reference55 articles.

1. World Health Organization Antiretroviral therapy for HIV infection in infants and children: Towards universal access 2010 http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf

2. Bristol-Myers Squibb SUMMARY OF PRODUCT CHARACTERISTICS - Sustiva http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/000249/WC500058311.pdf

3. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients;Marzolini;AIDS,2001

4. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study;Haas;AIDS,2004

5. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection;Csajka;Clin Pharmacol Ther,2003

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population;Clinical Pharmacology & Therapeutics;2024-06-04

2. Pharmacogenomics and adverse effects of anti‐infective drugs in children;Clinical and Experimental Pharmacology and Physiology;2023-10-15

3. Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia;CPT: Pharmacometrics & Systems Pharmacology;2023-03-23

4. Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives;Pediatric Drugs;2023-01-27

5. Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations;Journal of Personalized Medicine;2022-12-05